194 related articles for article (PubMed ID: 35796438)
21. [Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia].
Liu Y; Tang JY; Xu C; Gu LJ; Xue HL; Chen J; Pan C; Dong L; Zhou M
Zhonghua Er Ke Za Zhi; 2009 May; 47(5):366-70. PubMed ID: 19573409
[TBL] [Abstract][Full Text] [Related]
22. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
[TBL] [Abstract][Full Text] [Related]
23. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
24. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
Baraka A; Sherief LM; Kamal NM; Shorbagy SE
Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
[TBL] [Abstract][Full Text] [Related]
25. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.
Cherian S; Miller V; McCullouch V; Dougherty K; Fromm JR; Wood BL
Cytometry B Clin Cytom; 2018 Jan; 94(1):112-120. PubMed ID: 27598971
[TBL] [Abstract][Full Text] [Related]
26. Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.
Gao Q; Liu Y; Aypar U; Baik J; Londono D; Sun X; Zhang J; Zhang Y; Roshal M
Cytometry B Clin Cytom; 2023 Jul; 104(4):279-293. PubMed ID: 36999235
[TBL] [Abstract][Full Text] [Related]
27. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
Cáp J; Babusíková O; Kaiserová E; Jamárik M
Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
[TBL] [Abstract][Full Text] [Related]
28. Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy.
Mikhailova E; Illarionova O; Komkov A; Zerkalenkova E; Mamedov I; Shelikhova L; Olshanskaya Y; Miakova N; Novichkova G; Karachunskiy A; Maschan M; Popov A
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358863
[TBL] [Abstract][Full Text] [Related]
29. Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts.
Uckun FM; Song CW
Blood; 1993 Mar; 81(5):1323-32. PubMed ID: 8443393
[TBL] [Abstract][Full Text] [Related]
30. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
Verbeek MWC; van der Velden VHJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
32. Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia.
Wilson K; Case M; Minto L; Bailey S; Bown N; Jesson J; Lawson S; Vormoor J; Irving J
Haematologica; 2010 Apr; 95(4):679-83. PubMed ID: 19951974
[TBL] [Abstract][Full Text] [Related]
33. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
34. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
Uckun FM; Haissig S; Ledbetter JA; Fidler P; Myers DE; Kuebelbeck V; Weisdorf D; Gajl-Peczalska K; Kersey JH; Ramsay NK
Blood; 1992 Jun; 79(12):3369-79. PubMed ID: 1375851
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of the immunophenotype of patients with B lineage acute lymphoblastic leukemia at diagnosis and relapse].
Liu YR; Chang Y; Fu JY; Cheng YF; Zhang LP; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):335-8. PubMed ID: 16875586
[TBL] [Abstract][Full Text] [Related]
36. Immunophenotypic challenges in diagnosis of CD79a negativity in a patient with B acute lymphoblastic leukemia harboring intrachromosomal amplification of chromosome 21: a case report.
Berhili A; Bensalah M; ElMalki J; Elyagoubi A; Seddik R
J Med Case Rep; 2021 Oct; 15(1):531. PubMed ID: 34706776
[TBL] [Abstract][Full Text] [Related]
37. Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies.
Cherian S; Stetler-Stevenson M
Curr Protoc Cytom; 2018 Oct; 86(1):e44. PubMed ID: 30212602
[TBL] [Abstract][Full Text] [Related]
38. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
[TBL] [Abstract][Full Text] [Related]
39. A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Popov A; Henze G; Roumiantseva J; Budanov O; Belevtsev M; Verzhbitskaya T; Boyakova E; Movchan L; Tsaur G; Fadeeva M; Lagoyko S; Zharikova L; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Fechina L; Aleinikova O; Karachunskiy A
Pediatr Blood Cancer; 2023 Jun; 70(6):e30295. PubMed ID: 36975157
[TBL] [Abstract][Full Text] [Related]
40. Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
Xia M; Zhang H; Lu Z; Gao Y; Liao X; Li H
J Pediatr Hematol Oncol; 2016 Aug; 38(6):418-22. PubMed ID: 27438018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]